PolymarketBeschikbaarheid controlerenGeen KYCGeverifieerde afwikkelingsgegevensGoed gekalibreerdHuidige impliciete kans
December 31, 67%Koploper van 3 uitkomsten
December 31, 67%Marktkwaliteit
63 / 100
Gemiddelde kwaliteit24u volume
€ 276
Liquiditeit
€ 18,1K
Gemiddelde liquiditeitSpread
1.0 pt
Strakke spreadReacties
0
Marktdata
Bijgewerkt 7 minuten geleden
19 aug 26, 17:49 UTC1 jan 28, 04:59 UTC
Trends
Voorwaarden van het handelsplatform
Bron: Polymarket
Deze voorwaarden zijn ter informatie; voor gesimuleerd handelen bij CoinRithm gelden eigen regels.
- Minimumorder (aandelen):
- 5
- Prijsstap:
- 1 procentpunten
- Kosten:
- Ja
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
Is Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsIs Rosie the dog's AI-designed mRNA cancer vaccine legitimate?
Manifold MarketsSkin cancer vaccine BLA submitted by which date?
PolymarketWill the Russian cancer vaccine work?
Manifold MarketsFDA approves Retatrutide this year?
PolymarketFDA approves YCT-529 male birth control pill before 2035?
Manifold MarketsRegels
This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants approval of intismeran autogene for any indication by December 31, 2027, 11:59 PM ET.
- Otherwise, this market will resolve to "No".
- Intismeran autogene refers to the individualized neoantigen therapy developed by Moderna and Merck and evaluated in the Phase 3 INTerpath-001 trial (NCT05933577), also known as mRNA-4157 and V940, together with any brand, trade, or nonproprietary name later assigned to that product, as well as any renamed or modified version that the relevant company or the FDA identify as the same product or a direct continuation of the V940/mRNA-4157 program.
- Differences in neoantigen composition between patients will not affect resolution.
- Changes to the product's formulation will not affect resolution, provided the FDA approves the product described above.
- Approval as part of a combination regimen will qualify.
